Oramed Pharmaceuticals, Inc. (ORMP) Expected to Post Q1 2018 Earnings of ($0.21) Per Share
Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) – Equities researchers at B. Riley issued their Q1 2018 earnings per share (EPS) estimates for shares of Oramed Pharmaceuticals in a report released on Monday. B. Riley analyst A. D’silva anticipates that the biotechnology company will post earnings per share of ($0.21) for the quarter. B. Riley has a “Buy” rating and a $20.00 price target on the stock. B. Riley also issued estimates for Oramed Pharmaceuticals’ Q2 2018 earnings at ($0.28) EPS, Q3 2018 earnings at ($0.31) EPS, Q4 2018 earnings at ($0.33) EPS, FY2018 earnings at ($1.13) EPS, FY2019 earnings at ($1.53) EPS, FY2020 earnings at ($2.11) EPS, FY2021 earnings at ($2.10) EPS and FY2022 earnings at ($1.08) EPS.
ORMP has been the subject of a number of other research reports. HC Wainwright reissued a “buy” rating and set a $25.00 target price on shares of Oramed Pharmaceuticals in a research report on Wednesday, November 22nd. ValuEngine raised shares of Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, September 6th.
A number of large investors have recently added to or reduced their stakes in the business. Susquehanna International Group LLP acquired a new stake in Oramed Pharmaceuticals during the 3rd quarter valued at approximately $185,000. Virtu KCG Holdings LLC acquired a new stake in Oramed Pharmaceuticals during the 2nd quarter valued at approximately $125,000. Finally, Wells Fargo & Company MN increased its position in Oramed Pharmaceuticals by 4.4% during the 2nd quarter. Wells Fargo & Company MN now owns 14,725 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 625 shares during the period. 2.03% of the stock is owned by institutional investors and hedge funds.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.